Circulating tumor markers: Predictors of incomplete cytoreduction and powerful determinants of outcome in pseudomyxoma peritonei

被引:27
|
作者
Kusamura, Shigeki [1 ]
Hutanu, Ionut [2 ]
Baratti, Dario [1 ]
Deraco, Marcello [1 ]
机构
[1] Fdn IRCCS Ist Nazl Tumouri Milano, Dept Surg, Peritoneal Surface Malignancy Program, I-20133 Milan, Italy
[2] Univ Med & Pharm Gr T Popa, Iasi, Romania
关键词
cytoreductive surgery; hyperthermic intraperitoneal chemotherapy; pseudomyxoma peritonei; circulating Tumor markers; prognosis; HYPERTHERMIC INTRAPERITONEAL CHEMOTHERAPY; APPENDICEAL ORIGIN; CARCINOEMBRYONIC ANTIGEN; SURFACE MALIGNANCY; CARCINOMATOSIS; SURGERY; CAPECITABINE; PERFORMANCE; MORBIDITY; TOXICITY;
D O I
10.1002/jso.23329
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background Incomplete cytoreduction (IC) is one of the main prognostic factor in pseudomyxoma peritonei (PMP). We evaluated the ability of preoperative Ca125, CEA, and Ca19-9 to predict IC and prognosis in PMP. Methods One hundred fifty-six cases elected candidate to cytoreductive surgery and hyperthermic intraperitoneal chemotherapy from 1996 to 2011 were included in the study. We assessed the: (1) optimal cut-off values for circulating Tumor markers (CTM) in predicting IC (residual disease >2.5mm) using receiver-operating characteristics (ROC); (2) discriminant power of CTM and risk prediction models for IC by calculating the area under ROC curve (AUC-ROC); (3) prognostic factors using Cox proportional-hazard model. Results Optimal cut-offs were 125U/ml for Ca125, 18ng/ml for CEA, and 89U/ml for Ca19-9. The AUCs-ROC were 0.76, 0.68, and 0.69 for Ca125, CEA, and Ca19-9, respectively. The addition of CTM to risk prediction model that considered preoperative clinicopathological factors increased marginally the AUC-ROC (0.80-0.84). Ca125>125U/ml, Ca19-9>89U/ml independently affected overall survival. Conclusions Preoperative CTMs were reasonable but not perfect discriminators of IC. Moreover, Ca125 and Ca19-9, using new cut-off values, were proven to be new strong prognostic factors that overcome the value of disease extension and histological subtype. J. Surg. Oncol. 2013;108:1-8. (c) 2013 Wiley Periodicals, Inc.
引用
收藏
页码:1 / 8
页数:8
相关论文
共 36 条
  • [31] Pre-operative plasma cell-free circulating tumor DNA and serum protein tumor markers as predictors of lung adenocarcinoma recurrence
    Isaksson, Sofi
    George, Anthony M.
    Jonsson, Mats
    Cirenajwis, Helena
    Jonsson, Per
    Bendahl, Par-Ola
    Brunnstrom, Hans
    Staaf, Johan
    Saal, Lao H.
    Planck, Maria
    ACTA ONCOLOGICA, 2019, 58 (08) : 1079 - 1086
  • [32] The Role of Micro-RNAs and Circulating Tumor Markers as Predictors of Response to Neoadjuvant Therapy in Locally Advanced Rectal Cancer
    De Palma, Fatima Domenica Elisa
    Luglio, Gaetano
    Tropeano, Francesca Paola
    Pagano, Gianluca
    D'Armiento, Maria
    Kroemer, Guido
    Maiuri, Maria Chiara
    De Palma, Giovanni Domenico
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2020, 21 (19) : 1 - 29
  • [33] Circulating tumor cell (CTC) and CA2729 as predictors of outcome in patients with metastatic breast cancer (MBC) in the prospective TBCRC 005 biomarker study.
    Bardia, A.
    Huang, P.
    Zhang, Z.
    Sokoll, L.
    Ingle, J. N.
    Carey, L. A.
    Lin, N. U.
    Nanda, R.
    Viswanathan, K.
    Wolff, A. C.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [34] Inflammatory markers-serum level of c-reactive protein, tumor necrotic factor-α, and interleukin-6 as predictors of outcome for peripartum cardiomyopathy
    Sarojini A.
    Sai Ravi Shanker A.
    Anitha M.
    The Journal of Obstetrics and Gynecology of India, 2013, 63 (4) : 234 - 239
  • [35] Circulating Tumor DNA Dynamics as Early Outcome Predictors for Lisocabtagene Maraleucel as Second-Line Therapy for Large B-Cell Lymphoma from the Phase 3 TRANSFORM Study
    Stepan, Lara
    Ansari, Sahar
    Okal, Abood
    Dell'Aringa, Justine
    Thompson, Ethan
    Crotta, Alessandro
    Chow, Victor A.
    Abramson, Jeremy S.
    Kamdar, Manali
    Chabon, Jacob J.
    Hogan, Gregory
    Kurtz, David M.
    Alizadeh, Ash A.
    Peiser, Leanne
    BLOOD, 2023, 142
  • [36] Circulating matricellular fibrosis markers TSP2, IGFBP7, TSP4 and M2-macrophage marker CD163 as predictors of fibrosis and outcome in people with primary sclerosing cholangitis
    Horst, Ludwig J.
    Surabattula, Rambabu
    Katja, Fussel
    Sebode, Marcial
    Lohse, Ansgar W.
    Schuppan, Detlef
    Schramm, Christoph
    JOURNAL OF HEPATOLOGY, 2024, 80 : S265 - S265